Moderator
Tennessee
Moderator
Joined: 01/19/2004
View Profile
|
Note:the above post does NOT pertain to Moderna or Pfizer vaccines.
|
silversand
Montreal
Senior Member
Joined: 09/12/2004
View Profile
|
Canadians:
....I just finished listening to, 3 minutes ago a live Q & A with Canadian Deputy Prime Minister, Chrystia Freeland.
Q: ....why is Canada not receiving vaccines as the 16 countries are vaccinating hundreds of thousands a day ?
A: ....we are competing with extreme competition among EU countries that produce vaccines and are nationalizing production (particularly Pfizer European production).
The 4 questions asked as to why Canada is in 17th place among the World's top vaccinating countries was answered by a deafening pregnant pause.
Reading between the lines: Canada will not be receiving any vaccines but a microscopic trickle before at the very earliest, April. But more likely, the end of this year. Virtually zero vaccine. IF Canada had a national plan to manufacture vaccine here in tis country (as a National Security requirement), we would not be in LAST PLACE begging the G20 for scraps.
I'm absolutely livid after listening to this this morning.
Silver
2004 Chevy Silverado 2500HD 4x4 6.0L Ext/LB Tow Package 4L80E Michelin AT2s| Outfitter Caribou
|
qtla9111
Monterrey, Mexico
Senior Member
Joined: 09/17/2003
View Profile
 Offline
|
This article is dated January 15, 2021. Plans are underway to manufacture the vaccine in the northern Mexican state of Nuevo Leon.
Mexican State Poised To Purchase and Produce Russian Sputnik V Vaccine
2005 Dodge Durango Hemi
2008 Funfinder 230DS
Living and Boondocking Mexico Blog
|
silversand
Montreal
Senior Member
Joined: 09/12/2004
View Profile
|
.....hmmm. This is very interesting.
AstraZeneca's expected production and supply to the EU (Europe) has been severely rolled-back (something like 60 million doses in the coming quarter) due to that pesky key manufacturing ingredient shortfall. This does not affect Moderna nor Pfizer vaccines
Because of the European Union's Commission on vaccine approval/supply's worries that the EU will experience severe AstraZeneca shortfalls, the Commission will be exclusively taking the export decision to curtail export abroad of ALL vaccines manufactured in the EU 27 member States (ie. to Canada and other nations not EU 27 members). So, in effect, the EU will levy export controls on ALL vaccines produced by the EU 27 (remember: this does not include the UK). This European vaccine war does not affect the US supply at all
PharmaForum:
Dateline: Jan 26th
here-->
|
silversand
Montreal
Senior Member
Joined: 09/12/2004
View Profile
|
Gtla9111 wrote:This article is dated January 15, 2021. Plans are underway to manufacture the vaccine in the northern Mexican state of Nuevo Leon.
OK. There are two facets here: Russia selling their Sputnik vaccine doses....the other is manufacturing it. In my mind, unless that State has the manufacturing facilities already up and running (??), it will take a year of more to set up a vaccine manufacturing plant there.
Standing by to see how many Sputnik vaccines are scheduled to be delivered.....and when.
|
|
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
This is part of a press release from Moderna. I will post a link to the preprint of this study once it is available.
Quote:The in vitro study assessed the ability of mRNA-1273 to elicit potently neutralizing antibodies against the new SARS-CoV-2 variants, using sera from eight Phase 1 clinical trial participants (aged 18-55 years) who received two 100 µg doses of mRNA-1273, and separately using sera from non-human primates (NHPs) immunized with two doses of 30 µg or 100 µg of mRNA-1273.
For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants.
For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.
Moderna: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
I’m fairly certain I know how these tests were performed; I may even know the lab where they were run.
|
Deb and Ed M
SW MI & Space Coast, FL USA
Senior Member
Joined: 06/07/2004
View Profile
|
BCSnob wrote:This is part of a press release from Moderna. I will post a link to the preprint of this study once it is available.
Quote:The in vitro study assessed the ability of mRNA-1273 to elicit potently neutralizing antibodies against the new SARS-CoV-2 variants, using sera from eight Phase 1 clinical trial participants (aged 18-55 years) who received two 100 µg doses of mRNA-1273, and separately using sera from non-human primates (NHPs) immunized with two doses of 30 µg or 100 µg of mRNA-1273.
For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants.
For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While the Company expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.
Moderna: Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
I’m fairly certain I know how these tests were performed; I may even know the lab where they were run.
Putting this into plain talk: the Moderna vaccine as it stands, will be effective against the UK strain; but we may need a different booster once the S African variant takes hold (and surely it will), because the original vaccine weakens faster?
|
Deb and Ed M
SW MI & Space Coast, FL USA
Senior Member
Joined: 06/07/2004
View Profile
|
BCSnob wrote:
I’m fairly certain I know how these tests were performed; I may even know the lab where they were run.
I really appreciate you (and others!) providing this no-BS, no-Bias, non-political information. I just want to follow the science.
|
Moderator
Tennessee
Moderator
Joined: 01/19/2004
View Profile
|
![[emoticon]](http://www.coastresorts.com/sharedcontent/cfb/images/smile.gif "smile")
|
BCSnob
Middletown, MD
Senior Member
Joined: 02/23/2002
View Profile
|
Quote:Putting this into plain talk: the Moderna vaccine as it stands, will be effective against the UK strain; but we may need a different booster once the S African variant takes hold (and surely it will), because the original vaccine weakens faster?
I think what Moderna was trying to say is the SARS-CoV-2 virus produced a variant (mutations) that their vaccine is less effective against. It’s not that the vaccine is weakening (producing less antibodies since inoculation but the the antibodies produced are not as effective against this new variant.
|
|
|
